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The study “Sex- and gender-sensitive prevention of cardiovascular and metabolic 
disease in older adults in Germany”, the GendAge study, focusses on major risk 
factors for cardiovascular and metabolic diseases and on the development of major 
outcomes from intermediate phenotypes in the context of biological sex and gender 
differences. It is based on a re-investigation of participants of the Berlin Aging Study 
II (BASE-II). The Berlin Aging Study II (BASE-II) is aiming at identifying factors that 
distinguish healthy from unhealthy ageing and completed baseline assessments in 
2,200 adult volunteers (1,600 participants aged 60-80 years and 600 participants 
aged 20-35 years) in 2014. The BASE-II follow-up assessments of 1,100 men and 
women aged 65-94 years in 2018-2020 were part of GendAge. In addition to re-
assessing most baseline measures (geriatrics, internal medicine, immunology and 
psychology) we implemented a comprehensive gender questionnaire covering socio-
cultural gender characteristics and added high-quality echocardiography. 
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The original BASE-II cohort 
The Berlin Aging Study II (BASE-II) was launched as a multidisciplinary study aiming at 
identifying factors that distinguish ‘healthy’ from ‘unhealthy’ ageing. Baseline recruitment of 
2,200 adult volunteers from the Berlin metropolitan area and baseline assessments were 
completed in 2014 1. The ascertainment protocol included the collection of data from different 
domains for each of the 1,600 participants aged 60-80 years and 600 participants aged 20-
35 years, namely geriatrics and internal medicine, immunology, genetics, psychology, 
sociology, and economics 1,2. 
BASE-II baseline data were used in a multitude of analysis projects focusing on key 
questions revolving around age and aging. Research topics of the ongoing study include, but 
are not limited to, cognitive aging 3-5, cardiovascular and metabolic health 6-8, sarcopenia and 
frailty 9,10, psychosocial factors of aging 11,12, genetic risk factors of aging and disease 13-15, 
the impact of characteristics of the neighborhood people are living in 16, as well as indicators 
of biological age 17,18 and immune biomarkers 19. For an overview of the BASE-II research 
foci and publications, refer to 20 and the BASE-II website 
(https://www.base2.mpg.de/en/project-information/publications). 
 
What is the reason for the new data collection? 
The study “Sex- and gender-sensitive prevention of cardiovascular and metabolic disease in 
older adults in Germany”, the GendAge study, focusses on major risk factors for 
cardiovascular and metabolic diseases and on the development of major outcomes from 
intermediate phenotypes in the context of biological sex and gender differences. Major 
outcomes include but are not limited to myocardial infarction (MI), heart failure (HF) and T2D, 
as well as mortality and quality of life. Major aim is the first systematic collection of follow-up 
data in BASE-II participants and the analysis of sex- and gender-related differences. Gender 
was obtained by a novel comprehensive gender questionnaire covering a range of socio-
cultural gender characteristics as a central instrument. This questionnaire contains an 
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adapted version of the gender questionnaire developed by Pelletier and colleagues 21  and 
additionally included the variables used to calculate a gender score retrospectively by 
making use of gender-related variables assessed at baseline 22. This gender questionnaire 
will be central to develop a second gender score (GS-II).  23.  
 
What will be the new areas of research? 
There is new knowledge showing that sex differences play a role in all major diseases, their 
prevention and treatment 24. Other studies showed that gender as the sociocultural 
dimension of disease affects disease and treatment outcomes and also well-being 21,25. The 
new areas of research cover the systemic inclusion of sex-specific analysis and the inclusion 
of gender. Aging interacts with sex and gender differences in health, but it is not clear, which 
mechanisms are most important. 
.  
GendAge aims to better understand, which mechanisms affect cardio-metabolic morbidity, 
mortality, and quality of life among older adults in a sex- and gender-sensitive manner. 
While on different occasions follow-up data were ascertained for questionnaire and cognitive 
data 5,26-30, as being part of the GendAge study this cohort profile update describes, the first 
comprehensive follow-up assessments in BASE-II that also includes a re-assessment of 
central variables in the areas of internal medicine and geriatrics. At the same time, the other 
BASE-II research foci established over the past 10 years as described above (and in 20) will 
be continued and strengthened by the transition of BASE-II into a longitudinal study. 
 
Who is in the cohort? 
The original BASE-II sample consisted of 2,200 participants from the greater metropolitan 
area of Berlin, Germany (baseline assessment between 2009 and 2014). The follow-up 
assessments within the GendAge study took place between 22 June 2018 and 10 March 
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2020 at the Charité Universitaetsmedizin Berlin. During the recruitment of the follow-up 
cohort, we approached all participants of the remaining pool of 1,428 subjects out of the 
originally 1,671 subjects who completed the baseline medical assessments at an age of 60 
years and older. Potential follow-up participants were contacted via telephone and an 
invitation letter containing the comprehensive participant’s information sheet and the letter of 
consent was sent at least five days before the scheduled first of two assessment days to all 
subjects who agreed to participate at least five days before the scheduled first of two 
assessment days. Additionally, we included 17 subjects of the older age group who were not 
medically assessed at baseline, but were part of the BASE-II sample with data collected from 
at least one of the BASE-II partner sites. As presented in the flow chart (Figure 1), this 
resulted in a total of 1,100 participants of the older BASE-II group investigated in the follow-
up. These older participants had a mean age of 75.60 years (SD ± 3.77, range 64.91 - 94.07 
years), with up to 10.37 years of follow-up (N=1,083, mean follow-up at 7.35 years, (SD ± 
1.46), range 3.91 - 10.37). At baseline, the BASE-II included a group of 600 younger subjects 
aged 20-35 years serving as a reference population 1, of which 500 completed baseline 
medical assessments. Between 7 February 2020 and 13 March 2020, we performed follow-
up assessments in a total of 64 participants of this younger group until these assessments 
were suspended because of the SARS-Cov2 pandemic. These younger participants had a 
mean age of 36.81 years (SD ± 3.46, range 29.32 - 44.05 years), with up to 10.7 years of 
follow-up (minimum 6.08 years, mean follow-up at 8.16 years, SD ± 1.58). 
At follow-up, almost all of the older participants were retired (97.3%) as compared with 86% 
at the time of baseline assessment. At baseline, BASE-II participants were characterized by 
higher education and better self-reported health status than the general population of Berlin 
and Germany 1. At follow-up, this selection seems to have increased, with 68.8% of the 
participants reported to have a high school degree (51% at baseline) and about 61% rated 
their health as very good or good (40% at baseline). The rate of divorce had been above 
average at baseline with 29% and had dropped to 21.7% at follow-up, which is still 
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significantly above the German and Berlin average (i.e. 12.0% and 17.4%, respectively)31, 
while the proportion of widowed participants increased from 5% at baseline to 10.5% in the 
follow-up dataset of older BASE-II participants. As shown in Table 1, differences between 
men and women are evident with respect to the sociodemographic status and psychosocial 
functioning in the follow-up cohort: Men reported significantly higher school degrees and 
higher satisfaction with life in general than women. Interestingly, self-rated health did not 
differ between men and women, which matches to the overall morbidity estimated by an 
adapted version of the Charlson morbidity index 17,32, which also did not differ between men 
and woman (p=0.981, Table 1). This morbidity index, however, increased between baseline 
and follow-up (p<0.001, Wilcoxon signed-rank test and data not shown). Differences between 
men and women exist in the follow-up dataset with respect to the prevalence of some, but 
not all cardiovascular risk factors and diseases (Table 1). Men for example had a higher BMI 
and a higher proportion of men reported to have T2D and myocardial infarction than women. 
No significant differences between men and women were evident in the reporting of 
hypertension, peripheral artery disease, and stroke. With the aim of achieving a particularly 
high quality standard in the assessment of participant’s medical history at baseline and 
follow-up, including past and current diseases, the information given by the participants was 
recorded from study physicians as part of a structured one-to-one interview, allowing to 
consider its plausibility. This, however, does not cover the gap between reported 
(anamnestic) diseases and the diseases diagnosed in the course of the study. This is 
exemplified by T2D, which was reported by 15.6% and 8.8% of men and women, 
respectively. In contrast, this disease was diagnosed in 20.7% of men and 13.3% of women 
based on the ESC criteria 2019 33, indicating that a substantial proportion of almost 30% was 
unaware of the disease. The T2D prevalence increased from 12.7% at baseline to 16.7% at 
follow-up in the total cohort. 
What has been measured?  
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With the aim of investigating human ageing processes in BASE-II under consideration of 
different disciplines and longitudinally, the baseline investigation aimed at the most 
comprehensive data collection possible. At follow-up, most of these data in the field of 
geriatrics, internal medicine and psychology were again part of the study protocol (for a 
select overview, see Table 2). As the follow-up assessment being part of the GendAge study, 
we have implemented a comprehensive gender questionnaire covering a range of socio-
cultural gender characteristics as a central instrument. This questionnaire contains an 
adapted version of the gender questionnaire developed by Pelletier and colleagues 21 and 
additionally included the variables used to calculate a gender score retrospectively by 
making use of gender-related variables assessed at baseline 22. This gender questionnaire 
will be central to develop a second gender score (GS-II) and to reach the GendAge goals. 
With a focus on cardio-metabolic diseases in GendAge, we extended the broad range of data 
assessed in this area at baseline by echocardiography. Data on right and left ventricular and 
atrial morphology and systolic and diastolic function and vascular stiffness were obtained by 
a trained investigator (US) on a General Electric Vivid T8 R3 System and analyzed by a 
trained analyst (ET). 10% of echo analysis were controlled by an independent supervisor. 
The intraclass correlation coefficient (ICC) between analyst and independent supervisor was 
0.87 (LV IVSd: 0.86, LVEDV Biplane: 0.95, LVEF Biplane: 0.87, E/A: 093). LVEF was higher 
in women than in men, in agreement with most recent publications, and probably partially 
due to higher rate of MI in men34.  
Peripheral blood mononuclear cells were prepared from 903 participants at follow-up and 
frequencies as well as absolute counts of recent thymic emigrants (RTEs), TEMRA effector T 
cell subsets (TEMRA) and cytotoxic CD4+ T cells were directly assessed. While RTEs are 
known to decrease with ageing 35, alterations in TEMRA and specialised cytotoxic CD4+ T cell 
compartments can be indicative of age-related perturbations of systemic T cell immunity 36. 
Similar to baseline, we determined numerous routine laboratory parameters from blood and 
urine (Table 2), and also stored blood plasma/serum and urine samples for future analyses. 
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Genomic DNA was already extracted from EDTA-blood and buccal swab samples from 
GendAge participants, which will be used e.g. for the profiling of genome-wide DNA 
methylation signatures and new genome-wide single nucleotide polymorphism genotyping 
experiments (Table 2). In-between the two assessment days at the Charité, participants were 
asked to fill out a comprehensive psychosocial take-home questionnaire and return this at 
their second Charité visit. Moreover, another wave of cognitive assessments (see Table 2) 
carried out by the Max Planck Institute for Human Development (MPIB) has been tightly 
linked to the GendAge assessment of BASE-II participants. The cognitive session (= third 
study visit) was followed 7 days after the second medical examination and lasted about 4.5 
to 5 hours. Subjects were tested in groups of 4–6 individuals. The cognitive battery included 
17 measures of learning and memory performance, attention/processing speed, working 
memory, executive functioning, and perceptual speed (see Table 2). Within the week 
between study visit 2 (Charité) and 3 (MPIB) accelerometers (ActiGraph wGT3X-BT) have 
been used to track participants’ physical activity and sleep in a subset of our participants 
(N=750). 
After the cognitive session, participants were invited to take part in a one-to-one interview on 
a different day. This additional individual assessment took up to 60 minutes and serves as a 
cohort comparison between the BASE and BASE-II study populations. This additional data 
collection will also contribute to the BASE-II cognitive waves, allowing us to further 
investigate individual differences in aging trajectories (for an overview, refer to20). 
Furthermore, and as part of a collaboration with the Lifebrain study, a consortium of 
European studies funded by the EU Horizon 2020 Framework Programme37, we collected 
blood samples using dried blood cards, in order to determine laboratory parameters with 
identical methods used for all Lifebrain participating sites. Lifebrain aims at identifying 
determinants of healthy lifespan development by integrating and harmonizing data and 
results from 11 large and predominantly longitudinal European samples from 7 countries. 
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This has yielded a database of fine-grained measures focusing on brain and cognition from 
more than 7,000 individual participants. 
The GendAge study was approved by the Ethics Committee of the Charité–
Universitätsmedizin Berlin (approval number EA2/144/16) and all participants gave written 
informed consent. GendAge is registered in the German Clinical Trials Register (Study-ID: 
DRKS00016157). The cognitive battery was approved by the Ethics Committee of the Max-
Planck-Institute and the genomics experiments were approved by the Ethics Committees of 
the Charité (approval number EA2/144/16) and the University of Lübeck (approval numbers 
AZ19-390A and 19-391A). 
 
What has been found?  
GendAge was initiated in 2017 with a focus on sex and gender differences in the ongoing 
analyses of baseline BASE-II data in the area of cardio-metabolic risk factors and disease, 
some of which we would like to highlight here. The metabolic syndrome (MetS) combines the 
five cardiovascular risk factors of high waist circumference, low high density lipoprotein 
cholesterol, high fasting blood glucose, high triglycerides, and high systolic/diastolic blood 
pressure to diagnose the MetS based on cutoff values for each of the risk factors 38. While 
this approach is certainly useful in the clinical setting, it does not consider the full range of 
information of the continuously measured risk factors. We therefore applied confirmatory 
factor analysis to establish a latent metabolic load factor (MetL), representing a single 
continuous measure based on the five MetS risk factors. The MetL was on average 
significantly higher in men compared to women, and the factor was associated with more 
morbidity and poorer kidney function in both men and women, and with lower performance 
on a measure of cognitive function in men 7. Strong evidence suggests that higher levels of 
Lipoprotein (a) [Lp(a)] are an independent risk factor for coronary heart disease 39. 
Interestingly, at the same time higher Lp(a) is associated with a reduced type 2 diabetes 
(T2D) risk, a finding which has been reported from numerous studies, including BASE-II 
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. We recently analyzed the relationship between Lp(a) and cognitive performance 
assessed with the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)-Plus 
test battery. The results suggested that lower Lp(a) levels associate with better cognitive 
performance, at least in men 8. The analysis of arterial stiffness data from BASE-II assessed 
at baseline revealed sex differences in measures of arterial wave reflection, with an on 
average higher augmentation index in women than in men, a measure of endothelial function 
of the small and medium arteries. The results also suggested that women with exogenous 
intake of sex hormones for oral contraception and suppressed endogenous estradiol levels 
had higher levels of the augmentation index than non-users 42. T2D is an age-associated 
disease which is reflected by the 4.8% increase in the proportion of affected BASE-II 
participants within the 7.35 (SD ± 1.46) years between baseline 6 and follow-up 
assessments. This is even more dramatic since almost one third of the participants was not 
aware of the disease (Table 1). In addition being a risk factor for cardiovascular disease and 
cognitive decline, a recent analysis of BASE-II data suggested that the capacity to regulate 
the glucose metabolism is associated with well-being among older men 43. 
The immunological screening has so far revealed significantly higher frequencies of RTEs in 
women as compared to men, indicating a higher thymic T cell production even at the 
advanced ages of the GendAge participants. In men, more CD45RA+ re-expressing TEMRAs 
were detected than in women (Table 1). These cells are associated with chronic viral 
infections (e.g. CMV) and can serve as a signature of immune-senescence 44. We found no 
significant difference in the frequencies of cytotoxic CD4+ T cells. Together, these preliminary 
findings confirm the better immune status of aged women as compared to men. A detailed 
analysis of the datasets will identify additional correlates of sex and gender, aging, and the 
immune system.  
In GendAge, we have developed a retrospective gender score taking BASE-II baseline data 
reflecting sociocultural aspects (e.g., level of education, marital status, and chronic stress) 
into account. This gender score (GS-I) was associated with a number of clinical and 
psychosocial variables and performed better in predicting differences in a subset of variables 
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compared to biological sex 22. As mentioned above, we have implemented a comprehensive 
gender questionnaire as part of the follow-up assessments described here, including not only 
the variables required to re-calculate the GS-I based on the follow-up data, but also the items 
to develop an adapted version of the gender questionnaire proposed by Pelletier and 
colleagues 21. This gender questionnaire will be central to develop a second gender score 
(GS-II) and to reach the GendAge goals. 
 
What are the main strengths and weaknesses?  
The BASE-II follow-up assessments covered most of the medical, psycho-social and 
cognitive domains and variables assessed at baseline, and thereby taking the BASE-II 
characteristic of an exceptionally broad and in-depth data collection to a next, longitudinal 
level. In addition, and in the context of the GendAge focus on cardio-metabolic disease, we 
extended the assessments in this area e.g. by including high-quality echocardiography 
resulting in a unique data collection. This strength with respect to comprehensive and 
longitudinal data offers the potential to answer a number of questions that are of crucial 
relevance for the health of old women and men. Thus, GendAge will make important 
contributions for improvements in understanding the health and well-being of older adults in 
both genders. BASE-II was initiated as a multidisciplinary study with expertise in a broad 
range of fields relevant for aging research (e.g. internal medicine and geriatrics, biology, 
psychology, genetics, immunology, socio-economics, and now in GendAge further extended 
by socio-cultural aspects of gender). The past ten years of BASE-II research have shown 
that multidisciplinary collaboration is not only a statement of intent, but a fruit-bearing working 
posture and a clear strength of BASE-II. 
Sampling bias is a challenge which cohort studies have to deal with, and this is especially an 
issue in the follow-up of older study populations such as the older group of BASE-II 
participants. To address this, we have made a considerable effort (e.g. offering a taxi service 
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for participants not able to travel independently) to include as many participants in the follow-
up as possible. Additionally, and similar to baseline, we are able to systematically quantify 
the sampling bias and even account for it when it comes to the question of generalizability of 
study results to a population as a whole (e.g., Berlin or Germany), due to the evaluation of 
selectivity and representativeness via the German Socio-Economic Panel Study (SOEP) 1. 
Despite these possibilities we cannot rule out the possibility of a selection bias completely, 
which certainly is a weakness of this study, a weakness that applies to all cohort studies 
relying on voluntary participants who have been non-randomly recruited. With our direct 
comparability to the national representative SOEP study, we are in a position though to 
quantify the amount of selectivity and, if need, take measures to correct and adjust our 
results. 
 
Can I get hold of the data? Where can I find out more?  
More details on GendAge can be found at https://gendage.charite.de/en/ and information on 
the BASE-II as a whole is available at https://www.base2.mpg.de/en. BASE-II has a tradition 
of sharing data and biobank samples in joint collaborative projects which will be continued 
with respect to BASE-II data assessed in GendAge. Interested groups are invited to contact 
the study coordinating PI Ilja Demuth at ilja.demuth@charite.de for the data-sharing 
application form. Each application will be reviewed by the GendAge PIs (currently ID, VRZ 
and DG) and the decision communicated to the applicants usually within 4 weeks of 
submission.  
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Table 1: Selection of BASE-II follow-up characteristics as assessed of the GendAge 











Age (years) 1,100 75.7 (± 3.5) 75.5 (± 4.0) 0.276 
































































Satisfaction with life in 
general  1,097 7.9 (±1.6) 8.1 (±1.4) 0.034 
Digit Symbol Substitution 
Test3 1,095 41.82(±8.28) 39.65(±8.95) 3.4×10
-5
 
Depression (ever diagnosed) 1,095 122 (21.3%) 63 (12.0%) 5×10-5 
BMI 1,098 26.6 (±4.7) 27.4 (±3.7) 0.005 
Diabetes mellitus type II 
(self-reported) 1,097 49 (8.6%) 82 (15.6%) 3.7×10
-4
 
Diabetes mellitus type II 
(diagnosed/ ESC criteria 
2019) 




1,074 252 (45.5%) 327 (62.9%) 1.2×10-8 
Hypertension 1,097 296 (51.7%) 311 (59.2%) 0.013 
Myocardial infarction 1,097 11 (1.9%) 24 (4.6%) 0.015 
Stroke 1,096 13 (2.3%) 20 (3.8%) 0.158 
Peripheral artery disease 1,094 8 (1.4%) 15 (2.9%) 0.138 
Morbidity index 955 1.0 (IQR 2.0) 1.0 (IQR 2.0) 0.594 
Pulse wave velocity (m/s) 932 11.21 (±0.92) 11.04 (±0.91) 0.006 
Left ventricular ejection 
fraction (%) 774 64.16 (±6.42) 62.90 (±5.75) 0.004 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 




















Maximal hand grip strength 
(kg) 1,098 20.5 (±4.4) 35.1 (±6.8) 3.1×10
-236
 
Recent thymic emigrants 
(naïve CD4+ T cells) 395
3
 64.69 (± 16.34) 51.03 (± 13.69) 6.3x10-16 
TEMRA 
(effector memory T cells re-
expressing CD45RA) 
3954 32.82 (± 19.96) 34.94 (± 21.29) 0.309 
Cytotoxic SLAMF7+ CD4+ T 
cells 181
5
 6.02 (± 5.98) 6.05 (± 6.60) 0.974 
 
1Data are presented as N (%), mean ±standard deviation or median (interquartile range, IQR). 2Differences 
between women and men were assessed using the parametric t test, the nonparametric Mann-Whitney U test or 
the χ2 where appropriate. 3assessed at study visit 1  4903 expected to be available after completion of the 
analyses. 5700 expected to be available after completion of the analyses. 
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Table 2: BASE-II follow-up assessments during the three study visits in the GendAge 
study 




and medical history 
Medical history structured by organ systems, medication, body 
weight, height, lifestyle (including smoking status, alcohol 
consumption, physical activity) 
Physical status and 
functional tests 
Tinetti Mobility Test, Timed up & Go Test, Barthel Index (ADL), 
Lawton Instrumental Activities of Daily Living Scale (IADL), hand 
grip strength, anthropometric parameters, pulse wave velocity/ 
arterial stiffness (Mobil-o-Graph), echocardiography, 
electrocardiography (ECG), spirometry, motion monitoring 
(Actigraph), dual-energy X-ray absorptiometry (DXA)1,  
Psychological 
screening tests  
Mini Mental State Examination (MMSE), Digit Symbol 
Substitution Test (DSST)2, Center for Epidemiologic Studies 
Depression Scale (CESD) 
Questionnaires EPIC (food-frequency questionnaire), Gender Questionnaire, 
Pittsburgh Sleep Quality Index, Rapid Assessment of Physical 
Activity, SARC-F , SF-36  
Laboratory values3 Blood, serum or plasma: 25-hydroxyvitamin D, apolipoprotein 
A1, apolipoprotein B, basophiles, calcium, cortisol, creatinine, 
creatinine kinase, C-reactive protein, cystatin C, 
dehydroepiandrosterone, eosinophils, erythrozytes, ferritin, folic 
acid, gamma-glutamyltransferase, glucose 1, glucose 24, 
glutamate, oxalacetate transaminase, glutamate-pyruvate 
transaminase, HbA1c, HDL-cholesterol, hematocrit, hemoglobin, 
homocysteine, international normalized ratio, iron, LDL-
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cholesterol, leukocytes, lipoprotein (a), lymphocytes, 
magnesium, MCH, MCHC, MCV, monocytes, neutrophils, 
oestradiol, osteocalcin, partial thromboplastin time, RDW, sex 
hormone-binding globulin, testosterone, thrombocytes, thyroid-
stimulating hormone, thyroxine, total-cholesterol, triglycerides, 
triiodothyronine, urea, uric acid, vitamin B12, zinc. 
 
Urine: albumine, creatinine, desoxypyridinoline, teststrip: 
bilirubin, blood (erythrocytes), glucose, ketones, leukocytes, 
nitrite, pH value, protein, specific weight, urobilinogen 
 
Dried blood cards: arsenic, brain derived neurotropic-factor, 
cadmium, chromium, fatty acids (C12:0, C14:0, C15:0, C16:0, 
C16:1n7, C17:0, C18:0, C18:1,t6-11, C18:1,c9, C18:1,c11, 
C18:2,n-6, C20:0, C18:3,n-6, C18:3,n-3, C20:1,n-9, C20:2,n-6, 
C22:0/C20:3,n-6, C20:4,n-6, C20:5,n-3, C24:0, C22:5,n-3, 
C22:6,n-3, unknown), HbA1c, hsCRP, lead, mercury, nickel, 
total-cholesterol 
Genomics  Genome-wide single nucleotide polymorphism genotyping using 
the “Global Screening Array” (Illumina, Inc.); genome-wide DNA 




Well-being, positive affect and negative affect, emotion 
regulation, stress, personality, control beliefs, domain-specific 
control, time perception, embitterment, loneliness, solitude, 
social activities, network structure, sexuality, risk behavior, etc. 
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Biobanking Blood plasma & serum, urine, DNA extracted from EDTA-blood 
and buccal swaps 
Cognitive tests Episodic memory (Picture-Word-Task, Face-Profession-Task, 
Object Location Task, Scene-Encoding, Verbal learning and 
memory test), Working memory (Letter Updating, Spatial 
Updating, Number-N-Back), Executive functioning / processing 
speed (Multi-Source-Interference Task, Digit Symbol 
Substitutions Test2, Fluid intelligence (Letter series, Number 




Cryopreservation of whole blood (SmartTube system) or isolated 
PBMCs, and serum samples. Direct ex vivo staining of recent 
thymic emigrants (RTE, CD31+ CD45RA+ CD4+ T cells), 
TEMRA (CD45RA+ CD8+ T cells), Tregs (CD25bright CD127- 
CD4+ T cells), cytotoxic CD4+ Tcells, amongst others using four 
different panels: 1) ImmunoCount Panel (CD45, CD3, CD56, 
CD19, CD16, CD14, CD123, CD1c); 2) RTE panel (CD3, CD4, 
CD8, CD45RA, CCR7, CD31, CD95, CD11a); 3) TREG panel 
(CD3, CD4, CD8, CD25, CD127); 4) Effector T cell panel (CD3, 
CD4, CD8, CD45RA, CCR7, SLAM-F7, IL-6R, CD57, PD-1). 
Panels were measured on MacsQuant 10 (Miltenyi), MacsQuant 
16 (Miltenyi) or LSR II (BD)  
1only available for older group; 2assessed at study visit 1 and 3, 3blood samples were drawn 
after a fasting period of at least 8 hours (if not otherwise indicated), 4post-load (75g glucose, 
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Additional BASE-II/GendAge investigators: 
Nikolaus Buchmanni, Peter Eibichii, Friederike Kendeliii, Maximilian Königiv, Christina M. Lillv, 
vi
, Maike Mangoldvii, Ahmad Tauseef Naumaniii, Kristina Normanviii, ix, Graham Pawelecx, xi, 
Elisabeth Steinhagen-Thiesseniv, Sarah Toepferiv, Valentin Max Vetteriv, Gert G. Wagner xii, 
Ursula Wilkenshoffi, Kilian Wistuba-Hamprechtxiii 
 
iCharité; Department of Cardiology, Charité - University Medicine Berlin (Campus Benjamin Franklin), 
Berlin, Germany; iiMax Planck Institute for Demographic Research, Rostock, Germany; iiiBerlin 
Institute for Gender in Medicine, Charité – Universitätsmedizin Berlin; ivCharité – Universitätsmedizin 
Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin 
Institute of Health; Department of Endocrinology and Metabolism, Berlin, Germany; vSection for 
Translational Surgical Oncology and Biobanking, Department of Surgery, University of Lübeck and 
University Medical Center Schleswig-Holstein, Campus Lübeck, 23552 Lübeck, Germany; viAgeing 
Epidemiology Research Unit, School of Public Health, Imperial College, London SW71, UK; 
viiRegenerative Immunology and Aging, BIH Center for Regenerative Therapies, Charité 
Universitatsmedizin Berlin, Berlin, Germany; viiiGerman Institute of Human Nutrition, Department of 
Nutrition and Gerontology, Potsdam-Rehbruecke (DIfE), Germany; ixCharité - Universitätsmedizin 
Berlin, Forschungsgruppe Geriatrie am EGZB, Berlin, Berlin, Germany; xDepartment of Immunology, 
University of Tübingen, Tübingen, Germany; xiHealth Sciences North Research Institute, Sudbury, ON, 
Canada; xiiGerman Socio-Economic Panel Study (SOEP); xiiiDivision of Dermatooncology Department 
of Dermatology, University of Tübingen, Tübingen, Germany. 
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